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Introduction 
Urachal adenocarcinoma is a rare cancer that 
arises from the embryological remnant of the 
urogenital sinus and allantois and is thought to 
comprise less than 1% of bladder cancers.1,2 
Mucinous adenocarcinoma is the most common 
subtype and presentation is similar to that of 
urothelial cancers, with hematuria and 
abdominal pain. Surgical resection is the first 
line treatment and better outcomes are seen with 
less advanced stage at diagnosis. Efficacy of 
chemotherapeutic regimens are being investi-
gated; current five year survival rates are less 
than 50%.1,2 We present this rare case of a 
gentleman diagnosed with mucinous urachal 
adenocarcinoma with peritoneal metastasis. 
 
Case Report 
A 70-year-old man was referred to our 
oncology clinic for an urachal tumor with 
peritoneal involvement diagnosed after inpatient 
workup for new onset ascites. The patient quit 
smoking 40 years prior and rarely drank alcohol. 
He had neither a family history of cancer nor 
any exposure to known environmental 
carcinogens.  
The physical exam was notable for 
abdominal distension and ascites, causing 
dyspnea and hypoxia. Neither the liver nor the 
spleen was palpable, and there was no 
lymphadenopathy. Abdominal paracentesis was 
performed. Cytological specimen showed 
cellular fluid with atypical cells. Staining with 
mucicarmine and periodic acid-Schiff after 
digestion (PAS-D) showed extra-cellular mucin 
and small intra-cytoplasmic globules, which 
supported a diagnosis of mucinous adeno-
carcinoma (Figure 1).  
 
 
Figure 1. Cytologic specimen showed mucin-
producing adenocarcinoma. 
 
Immunohistochemistry showed tumor cells 
that were positive for CK-7 and CEA-m, and 
negative for CK20 and CD15. The absence of 
CK20 staining indicated that a primary GI 
malignancy is unlikely. Evaluation of abdomen 
and pelvis by computed tomography (CT) 
showed extensive ascites. The entire omentum 
had soft tissue streaking. A large, partly 
calcified mass extended from the dome into the 
urachal process measuring 7.3 cm x 4.3 cm x 8 
cm (Figure 2). These histological and 
radiological findings confirmed the diagnosis of 
urachal carcinoma with peritoneal metastasis. 
Tumor stage was T4N0M1. A urologist 
recommended that surgical resection was not 
possible and referred the patient to oncology for 
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chemotherapy. Prior to chemotherapy, the 
patient was experiencing pain, dyspnea, and 
inability to carry out activities of daily living. 
Carcinoembryonic antigen (CEA) levels were 
18.3 ng/ml. The patient was started on 
FOLFOX6, which consists of oxaliplatin 85 
mg/m2 intravenous (IV) infusion with 
leucovorin (LV) 400 mg/m2 over two hours, 
followed by a 400 mg/m2 bolus of 5-FU, 
followed by an IV infusion of 5-FU 2400 
mg/m2 for 46 hours.  This regimen was repeated 
every two weeks. 
He responded well as abdominal distension, 
pain, and dyspnea decreased, performance status 
improved, and CEA (Figure 3) decreased after 
the second cycle.  
 
 
Figure 2. CT scan demonstrating calcific 
urachal mass. 
 
 
Figure 3. Carcinoembryonic antigen (CEA) 
response to 5-FU/FOLFOX treatment. 
 
A CT showed decrease in ascites and no 
increase in tumor size after third cycle. After 
cycle 14, the patient developed numbness in the 
fingers, which was attributed to chemotherapy-
induced peripheral neuropathy. In cycle 15, 
oxaliplatin was stopped, but leucovorin and 5-
FU were continued. At this point, CEA levels 
plateaued at 3.45 ng/ml (Figure 3). Four more 
cycles with 5-FU and leucovorin were given. 
After cycle 18, CEA started to rise and CT 
showed slight increase in size of tumor. After 
cycle 22, CEA increased further to 10.4-ng/mL 
and tumor size also continued to increase. 
However, the patient’s symptoms were well 
controlled. Second line chemotherapy with 
irinotecan was started, but the patient was 
unable to tolerate it due to severe vomiting. The 
patient opted for hospice and later died.  
 
Discussion 
The urachus is a remnant of the channel 
between the fetal urinary bladder and umbilicus. 
It is formed from the allantois between the 5th 
and 7th week of gestation and typically is sealed 
and obliterated by the 12th week. It is identified 
postnatally as the medial umbilical ligament.1 
Failure of the urachus to seal may result in 
patent urachus, cyst, fistula, diverticulum, or 
sinus. Urachal cancer may develop from these 
urachal remnants, and adenocarcinoma occurs in 
the vast majority of these cases, often mucin-
producing.2,3 It is a rare cancer and constitutes 
less than 1% of bladder tumors.4 
Risk factors are not well defined and do not 
appear to be related to bladder carcinogens.5,6 
Urachal adenocarcinoma is more common in 
men and onset is most often during middle age. 
Gross or microscopic hematuria is the most 
common presenting symptom, though 
abdominal pain, fullness, and other urinary 
symptoms have been reported.3,7,8 
The Sheldon criteria represent the 
significant clinical and pathological charac-
teristics of urachal cancer. These include the 
location of the tumor in the bladder dome or 
anterior wall, evidence of a sharp demarcation 
between the tumor and surface epithelium, the 
absence of cystitis, and exclusion of primary 
adenocarcinoma located elsewhere that has 
spread secondarily to bladder.9-13 If a biopsy of 
the bladder dome or tumor reveals adeno-
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carcinoma, urachal cancer should be suspected, 
and diagnosis may be confirmed with 
immunohistochemistry.12,14  
Urachal adenocarcinoma and colonic 
adenocarcinoma are histologically similar and 
associated with elevations in CEA and CA 19-9. 
No molecular markers have been discovered 
that have any prognostic implications.7 Urachal 
adenocarcinoma commonly recurs, often with 
peritoneal carcinomatosis, as well as metastasis 
to liver and lung. Surgical resection is the only 
curative treatment and includes complete 
resection of the tumor, urachus, and umbilicus 
as well as pelvic lymph node dissection.3,15-19 
The Sheldon TNM staging system or the 
Mayo staging system may be used for 
prognosis, both are about equally efficacious.7 
Negative surgical margins and no lymph node 
involvement are good prognostic indicators. 
Median survival is 48 months, with five year 
overall survival rate of 45%.5 However, 
presence or absence of metastasis affects 
survival,11 with 61% relative five-year survival 
in patients without metastatic disease, versus 
15% relative five-year survival in patients with 
metastatic disease.5 Chemotherapy may improve 
survival in patients with metastasis or lymph 
node involvement.16  
There is no established chemotherapy 
regimen for metastatic urachal carcinoma, but 
chemotherapy regimens used for colonic 
adenocarcinoma have been tried.9,16 Regimens 
of 5-FU and cisplatin have shown about 40% 
response in some studies.16,20 Efficacy of 
chemotherapy regimens are being 
investigated.3,19,21-23 
 
Conclusion 
Urachal adenocarcinoma is a rare cancer that 
occurs most often in middle-aged men. Surgical 
resection may provide cure in patients with 
early stage disease but chemotherapeutic 
responses are low and most of short duration. 
This case represented a significant response to 
the FOLFOX regimen.  
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